PubMed Journals Articles About "Global Gallbladder Cancer Therapeutics Market 2019 2023 Advent" RSS

18:51 EDT 15th September 2019 | BioPortfolio

Global Gallbladder Cancer Therapeutics Market 2019 2023 Advent PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Global Gallbladder Cancer Therapeutics Market 2019 2023 Advent articles that have been published worldwide.

More Information about "Global Gallbladder Cancer Therapeutics Market 2019 2023 Advent" on BioPortfolio

We have published hundreds of Global Gallbladder Cancer Therapeutics Market 2019 2023 Advent news stories on BioPortfolio along with dozens of Global Gallbladder Cancer Therapeutics Market 2019 2023 Advent Clinical Trials and PubMed Articles about Global Gallbladder Cancer Therapeutics Market 2019 2023 Advent for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Global Gallbladder Cancer Therapeutics Market 2019 2023 Advent Companies in our database. You can also find out about relevant Global Gallbladder Cancer Therapeutics Market 2019 2023 Advent Drugs and Medications on this site too.

Showing "Global Gallbladder Cancer Therapeutics Market 2019 2023 Advent" PubMed Articles 1–25 of 25,000+

Should we consider gallbladder cancer a new smoking-related cancer? A comprehensive meta-analysis focused on dose-response relationships.

The few studies on the association of smoking with gallbladder cancer risk have given conflicting results. Here we provide the most accurate and up-to-date quantification of the effect of cigarette smoking on gallbladder cancer risk, and investigate for the first time the dose-response relationships. Using an innovative approach for the identification of publications, we conducted a systematic review and meta-analysis of epidemiological studies published until March 2019 on the association of smoking with g...

Long non-coding RNA GBCDRlnc1 induces chemoresistance of gallbladder cancer cells by activating autophagy.

Gallbladder cancer is the most common biliary tract malignancy and not sensitive to chemotherapy. Autophagy is an important factor prolonging the survival of cancer cells under chemotherapeutic stress. We aimed to investigate the role of long non-coding RNAs (lncRNAs) in autophagy and chemoresistance of gallbladder cancer cells.

Silencing of long non-coding RNA FOXD2-AS1 inhibits the progression of gallbladder cancer by mediating methylation-dependent induction of MLH1.

In recent years, accumulating evidence has demonstrated the role of long non-coding RNAs (lncRNAs) in pathophysiological processes underlying gallbladder cancer. A microarray analysis identified that highly expressed lncRNA FOXD2-AS1 is associated with gallbladder cancer, and predicted its binding to the MutL homologue 1 (MLH1) promoter. Hence, we aimed to characterize the functional relevance of lncRNA FOXD2-AS1 in gallbladder cancer and the possible mechanisms associated with methylation of MLH1 in this s...

Overexpression of SNORA21 suppresses tumorgenesis of gallbladder cancer in vitro and in vivo.

Gallbladder cancer (GBC) ranks fifth in the most common malignancy of the gastrointestinal tract worldwide. It is reported many small nucleolar RNAs (SNORNs) could regulate the progression of GBC. To identify potential therapeutic targets for GBC, we conducted microarray analysis in GBC tissues and adjacent normal tissues. We found that SNORA21 was downregulated most in gallbladder tumor samples. Therefore, this research aimed to investigate the role of SNORA21 during the tumorigenesis of GBC.

Preoperative CT findings for prediction of resectability in patients with gallbladder cancer.

To predict residual tumor (R) classification in patients with a surgery for gallbladder (GB) cancer, using preoperative CT.

Glucose to Lymphocyte Ratio as a Prognostic Marker in Patients With Resected pT2 Gallbladder Cancer.

We designed a clinical application of glucose to lymphocyte ratio (GLR) as it might be a sensitive parameter to determine the glucose metabolism and behavior of the cancer (i.e., its aggressiveness), and the immunologic status of a patient with cancer. Thus, we investigated the association of GLR with the overall survival (OS) and disease-free survival (DFS) of patients with T2 gallbladder (GB) cancer after curative-intent surgery.

Effects of Sarcopenia on Prognosis After Resection of Gallbladder Cancer.

This study aimed to determine the prognostic significance of radiographic sarcopenia (RS) in patients with gallbladder cancer (GBC).

A case of successfully resected metachronous gastric and gallbladder metastases from pancreatic body cancer.

Pancreatic ductal adenocarcinoma (PDAC) readily metastasizes to the lymph nodes, liver, lung, and peritoneum; however, gastric and gallbladder metastases are rare. We report a case of metachronous gastric and gallbladder metastases from PDAC.

Market and Patent Analyses of Wearables in Medicine.

Wearable medical devices (WMDs) will advance point-of-care diagnostics and therapeutics. This article analyses the market and patents for wearable devices. Activity monitors have the largest market share, and the intellectual property landscape is dominated by electronics corporations. However, the majority of these patents have not been realized in commercial products.

Medical innovation, education, and labor market outcomes of cancer patients.

Innovations in cancer treatment have lowered mortality, but little is known about their economic benefits. We assess the effect of two decades of improvement in cancer treatment options on the labor market outcomes of breast and prostate cancer patients. In addition, we compare this effect across cancer patients with different levels of educational attainment. We estimate the effect of medical innovation on cancer patients' labor market outcomes employing tax return and cancer registry data from Canada and ...

Robotic Surgery as an Alternative Approach for Reoperation of Incidental Gallbladder Cancer.

An integrative view on breast cancer signature panels.

Breast cancer is heterogeneous with distinct clinical outcomes. Diverse types of markers are available on the market for breast cancer prognosis, diagnosis, and therapeutics, with distinct assay approaches. These, though they enlarge our selection pool for characterizing breast cancer patients and help improve the precision on the therapeutics, they can complicate our understanding and choice of marker panels. Areas covered: This review aims at classifying the commonly used marker panels according to their ...

Role of 99mTc-HIDA Scan for Assessment of Gallbladder Dyskinesia and Comparison of Gallbladder Dyskinesia with Various Parameters in Laparoscopic Cholecystectomy Patients.

Pathogenesis of gallstone includes bile stasis due to defect in the gallbladder muscle contraction. Our aim of the study is to find out the role of 99mTc-HIDA scan in assessment of gallbladder dyskinesia in cholelithiasis patients before laparoscopic cholecystectomy and compare the gallbladder dyskinesia with various parameters like symptoms of patients, diabetic status of patients, gallstones size and number, and cholecystitis features in histopathology report after surgery.

1st report of unexpected true left-sided gallbladder treated with robotic approach.

True left-sided gallbladder (T-LSG) occur when the gallbladder is positioned to the left of the ligamentum teres and falciform ligament and under the surface of the left liver lobe.

Diabetes Technol Ther 2019;21(8):415-422; DOI: 10.1089/dia.2019.0052.

Clinicopathological features and survival for gallbladder NEN: A population-based study.

Gallbladder neuroendocrine neoplasm (GB-NEN) is a relatively rare neoplasm, accounting for 0.5% of all neuroendocrine neoplasm cases and 2.1% of gallbladder cancers. Because of the limited understanding of GB-NEN, the aim of this study was to explore the clinicopathology and survival of GB-NEN patients selected from the Surveillance, Epidemiology, and End Results (SEER) database.

Nanoparticles for Nucleic Acid Delivery: Applications in Cancer Immunotherapy.

Immunotherapy has recently emerged as a powerful tool for cancer treatment. Early clinical successes from cancer immunotherapy have led to a growing list of FDA approvals, and many new therapies are in clinical and preclinical development. Nucleic acid therapeutics, including DNA, mRNA, and genome editing systems, hold significant potential as a form of immunotherapy due to its robust uses in cancer vaccines, adoptive T-cell therapies, and gene regulation towards the goal of treating cancer. However, these ...

Should Flanders consider lowering its target age for colorectal cancer screening to 45-49?

Colorectal cancer (CRC) screening generally starts screening by the age of 50 based on guidelines. Lately however, a U.S. guideline recommended to start CRC screening from age 45 and, very recently, two studies were published that addressed young-onset in Europe (in part) (Vuik et al., 2019; Araghi et al., 2019).

Brexanolone: First Global Approval.

Brexanolone (ZULRESSO™) is an intravenously administered, small molecule, neuroactive steroid GABA receptor positive allosteric modulator that was developed by Sage Therapeutics under license to the University of California for the treatment of postpartum depression (PPD). The formulation is a mixture of allopregnanolone, an endogenous inhibitory pregnane neurosteroid, and sulfobutylether-beta-cyclodextrin (a solubilizing agent). In mid-March 2019 brexanolone received its first global approval in the USA ...

2017-2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer.

Small cell lung cancer remains an aggressive, deadly cancer with only modest effect on survival from standard chemotherapy. However, with the advent of immunotherapy and comprehensive genomic and transcriptomic profiling, multiple new targets are showing promise in the clinical arena, and just recently PD-L1 inhibition has been shown to improve the efficacy of standard chemotherapy in extended disease SCLC. Our increasing understanding of the interactions between different pathways will enable more tailored...

Global, Regional, and National Burden of Testicular Cancer, 1990 - 2016: Results from the Global Burden of Disease Study 2016.

To provide estimates on the global incidence, mortality, and disability-adjusted life years (DALYs) associated with testicular cancer (TCa) between 1990 and 2016, using findings of the Global Burden of Disease (GBD) 2016.

Left side gallbladder with agenesis of right anterior sector and absence of right hepatic duct. A case report.

Left sided gallbladder is a rare congenital abnormality more often discovered as incidental finding during laparoscopic cholecystectomy requiring surgical challenge to prevent complication. We present a case of a true left sided gallbladder treated with laparoscopic cholecystectomy.

Burden of Gastric Cancer.

Gastric cancer is a global health problem, with more than 1 million people newly diagnosed with gastric cancer worldwide each year. Despite its worldwide decline in incidence and mortality over the past five decades, gastric cancer remains the third leading cause of cancer-related death. Knowledge of global as well as regional epidemiology and risk factors for gastric cancer is essential for the practicing gastroenterologist to make personalized decisions about risk stratification, screening and prevention....

NOP2/Sun RNA methyltransferase 2 promotes tumor progression via its interacting partner RPL6 in gallbladder carcinoma.

NOP2/Sun domain family, member 2 (NSUN2) is a nucleolar RNA methyl-transferase catalyzing 5-methylcytosine formation. Evidence shows that NSUN2 is correlated with cell unlimited proliferation. However, its functional role in gallbladder carcinoma (GBC), the most common biliary tract malignancy with poor prognosis, remains to be determined. Here we found that NSUN2 was highly expressed in GBC tissues as well as cell lines. NSUN2 silencing repressed GBC cell proliferation and tumorigenesis both in vitro and i...

Novel therapeutic interventions in cancer treatment using protein and peptide-based targeted smart systems.

Cancer, being the most prevalent and resistant disease afflicting any gender, age or social status, is the ultimate challenge for the scientific community. The new generation therapeutics for cancer management has shifted the approach to personalized/precision medicine, making use of patient- and tumor-specific markers for specifying the targeted therapies for each patient. Peptides targeting these cancer-specific signatures hold enormous potential for cancer therapy and diagnosis. The rapid advancements in...

Quick Search